Current HER2/neu-based vaccine trials are mostly associated with disease-free breast cancer patients who have completed the standard therapies, such as surgery, radiotherapy or chemotherapy (Carmichael et al. 2010; Clifton et al. 2017, 2020; Holmes et al. 2008; Mittendorf et al. 2014, 2016, 2019; Patel et al. 2021a, b; Peace et al. 2017). Here, ERBB2 is linked to breast cancer.